Abstract:Background: The approval of immune checkpoint therapies has revolutionized cancer treatment and established immuno-therapy as an additional treatment option. However, while anti-PD-(L)1 therapies have demonstrated durable responses, only a small subset of patients respond. One mechanism of tumor escape is via the release of immunosuppressive metabolites such as adenosine. CD73, an extracellular enzyme expressed on immune cells and some tumors, catalyzes the conversion of AMP to adenosine, the rate limiting step in adenosine production. As a strategy to improve response rates we developed a first in class CD73/PD-1 targeting DFC, comprised of a multivalent conjugate of a small molecule CD73 inhibitor stably linked to a proprietary human IgG1 Fc-fusion with a PD-1 inhibitor peptide. This multispecific DFC has the potential for differentiation and increased therapeutic potency compared to approved PD-(L)1 inhibitors. Methods: Binding of CD73/PD-1-001 to biotinylated hPD-1 was determined using ELISA and to human CD8+ T cells by flow cytometry. CD73 inhibition was measured in cell-free and cell-based assays. Efficacy was determined in a humanized mouse model optimized for PD-1 activity against a transgenic MC-38 colon cell line expressing hPD-L1 (Genoway, France). Tumor volumes were recorded and statistical analysis was conducted by t-test (Mann-Whitney) or two-way ANOVA. Results: In vitro, CD73/PD-1-001 demonstrated potent activity against both checkpoint targets. CD73/PD-1-001 bound to hPD-1 with an IC50 of < 1 nM and demonstrated functional inhibition of CD73 with an EC50 of 70% at dose concentrations of 3 mg/kg or greater (p≤0.01). However, at the lowest test concentration of 1 mg/kg, only CD73/PD-1-001 retained significant potency with a TGI of 56.0 % (p ≤ 0.05). Tumor reduction in the 1 mg/kg PD-1-001 group did not reach statistical significance (36.5%, p > 0.05). Conclusions: This work demonstrates that a multispecific CD73/PD-1 targeting DFC, is a potent inhibitor of tumor growth in a humanized mouse model. Furthermore, CD73/PD-1-001 was more potent than PD-1 monotherapy, demonstrating the therapeutic benefit of targeting two important checkpoints with a single agent molecule. Collectively, preclinical testing of a CD73/PD-1 DFC has validated the benefits of targeting the PD-(L)1 axis in combination with adenosine suppression, resulting in improved anti-tumor effects. Citation Format: James Levin, Simon Döhrmann, Nicholas Dedeic, Amanda Almaguer, Doug Zuill, Elizabeth Abelovski, Jason N. Cole, Jeffrey B. Locke, Joanne Fortier, Qiping Zhao, Maria Hernandez, Karin Amundson, Madison Moniz, Hongyuan Chen, Dhanya Panickar, Thanh Lam, Tom Brady, Allen Borchardt, Grayson Hough, Leslie W. Tari. Discovery of a multispecific CD73/PD-1 targeting drug Fc-conjugate (DFC), which improves tumor reduction compared to PD-1 monotherapy in a humanized mouse model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2728.

The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy

PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy

High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1

Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab

Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1

Ultra-stable Biomembrane Force Probe for Accurately Determining Slow Dissociation Kinetics of PD-1 Blockade Antibodies on Single Living Cells.

Structural Basis for Blocking PD-1-mediated Immune Suppression by Therapeutic Antibody Pembrolizumab

Investigation of Molecular Interactions Mechanism of Pembrolizumab and PD-1

A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab

Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction

Structural Basis of the Therapeutic Anti-Pd-l1 Antibody Atezolizumab.

Structural Basis of a Novel PD-L1 Nanobody for Immune Checkpoint Blockade

Bispecific Aptamer-Based Recognition-then-Conjugation Strategy for PD1/PDL1 Axis Blockade and Enhanced Immunotherapy

Abstract 2728: Discovery of a multispecific CD73/PD-1 targeting drug Fc-conjugate (DFC), which improves tumor reduction compared to PD-1 monotherapy in a humanized mouse model

Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges

Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics

Abstract 1875: Novel cell-based bioassays for monoclonal antibody and bispecific molecules in PD-1 blockade monotherapy and combination therapy

Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging

Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti–programmed cell death protein-1 (PD-1) antibody, in human cancer models

High-Affinity Decoy PD-1 Mutant Screened from an Epitope-Specific Cell Library